↓ Skip to main content

Luteolin as a therapeutic option for multiple sclerosis

Overview of attention for article published in Journal of Neuroinflammation, October 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
4 X users
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
65 Dimensions

Readers on

mendeley
71 Mendeley
Title
Luteolin as a therapeutic option for multiple sclerosis
Published in
Journal of Neuroinflammation, October 2009
DOI 10.1186/1742-2094-6-29
Pubmed ID
Authors

Theoharis C Theoharides

Abstract

Multiple sclerosis (MS) remains without an effective treatment in spite of intense research efforts. Interferon-beta (IFN-beta) reduces duration and severity of symptoms in many relapsing-remitting MS patients, but its mechanism of action is still not well understood. Moreover, IFN-beta and other available treatments must be given parenterally and have a variety of adverse effects. Certain naturally occurring flavonoids, such as luteolin, have anti-oxidant and anti-inflammatory effects, including inhibition of activated peripheral blood leukocytes from MS patients. Luteolin also inhibits mast cells, as well as mast cell-dependent T cell activation, recently implicated in MS pathogenesis. Moreover, luteolin and structurally similar flavonoids can inhibit experimental allergic allergic encephalomyelitis (EAE), an animal model of MS in rodents. An appropriate luteolin formulation that permits sufficient absorption and reduces its metabolism could be a useful adjuvant to IFN-beta for MS therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 1 1%
France 1 1%
Belgium 1 1%
Canada 1 1%
Unknown 67 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 18%
Student > Bachelor 10 14%
Researcher 7 10%
Student > Master 7 10%
Student > Postgraduate 6 8%
Other 10 14%
Unknown 18 25%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 27%
Medicine and Dentistry 12 17%
Biochemistry, Genetics and Molecular Biology 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Neuroscience 3 4%
Other 12 17%
Unknown 17 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2022.
All research outputs
#4,127,714
of 25,374,647 outputs
Outputs from Journal of Neuroinflammation
#843
of 2,951 outputs
Outputs of similar age
#16,117
of 105,837 outputs
Outputs of similar age from Journal of Neuroinflammation
#2
of 8 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,951 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 105,837 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.